No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 85-93

  Hegewisch Becker, S ^a   Staib, F ^a   Loning T ^a   Pichlmeier, U ^a   Kroger N ^a   Reymann, A ^a   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; MDR1 gene; Multidrug resistance; P glycoprotein; Rhodamine 123

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031929861     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008255725515     Document Type: Article

References (39)

1. Neyfakh AA. Use od fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 1988; 174: 168-76.
2. Hegewisch-Becker S, Hossfeld DK. The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Ann Hematol 1996; 72: 105-17.
3. Chan HSL, De Boer G, Haddad G, Gallie LB, Ling V. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 1995; 9: 275-318.
4. Leighton JC, Goldstein LJ. P-glycoprotein in adult solid tumors: Expression and prognostic significance. Hematol Oncol Clin North Am 1995; 9: 251-73.
5. Roessner A, Ueda Y, Bockhorn-Dworniczak B et al. Prognostic implication of immunodetection of P-glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol 1993; 119: 185-90.
6. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-5.
7. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9: 363-82.
8. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-31.
9. Linn SC, Giaccone G, van Diest PJ et al. Prognostic relevance of P-glycoprotein expression in brest cancer. Ann Oncol 1995; 6: 679-85.
10. Charpin C, Vielh P, Duffaud F et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994; 86: 1539-45.
11. Torre de la M, Larsson R, Nygren P et al. Expression of the multidrug-resistance gene product in untreated human breast cancer and its relationship to prognostic markers. Acta Oncol 1994; 33: 773-7.
12. Wishart GC, Plumb JA, Going JJ et al. P-Glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62, 758-61.
13. Ro J, Sahin A, Ro JY et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990; 21: 787-91.
14. Drach D, Zhao S, Drach J, Mahadevia R et al. Subpopulations of normal peripheral blood and bone marrow cells espress a functional multidrug resistance phenotype. Blood 1992; 80: 2729-34.
15. Beck WT, Grogan TM, Willman CL et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 1996; 56: 3010-20.
16. Charpin C, Devictor B, Bonnier P et al. Expression of Her-2/neu oncogene in breast cancer: Correlation of quantitative immunocytochemistry and prognostic factors. Int J Oncol 1992; 1: 815-23.
17. Paik S, Hazan R, Fisher ER, Sass RE et al. Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 102-12.
18. De Potter CR, Schelfhout AM. The neu-protein and breast cancer. Virchows Archiv 1995; 426: 107-15.
19. Iglehart JD, Kraus MH, Langton BC et al. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990; 50: 6701-7.
20. Van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. N Engl J Med 1988; 319: 1239-45.
21. Limon J, Dal Cin P, Sandberg AA. Application of long-term collagenase disaggregation for cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet 1986; 23: 305-13.
22. Stein U, Walther W, Lemme M et al. Development and characterization of novel human multidrug resistant memory carcinoma lines in vitro and in vivo. Int J Cancer 1997; in press.
23. Hegewisch-Becker S, Hannania EG, Fu S, Körbling M et al. Transduction of MDR1 into human and mouse hematopoietic progenitor cells: Use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol 1995; 90: 876-83.
24. Visser JWM, Van den Engh GJ, Van Bekkum DW. Light scattering properties of murine hematopoietic cells. Blood Cells 1980; 6: 391-407.
25. Hegewisch-Becker S, Faltz C, Hossfeld DK. Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells. Eur J Haematol 1996; 56: 12-22.
26. Noonan KE, Beck C, Holzmayer TA, Chin JE et al. Quantitative analysis of mdrl (multidrug resistance) gene expression in human tumours by polymerase chain reaction. Proc Natl Acad Sci 1990; 87: 7160-4.
27. Van der Valk P, Van Kalken CK, Ketelaars H et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1990; 1: 56-64.
28. Dalton WS, Grogan TM, Rybski JA et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug resistant human myeloma cells: Association with levels of drug resisatnce and drug accumulation. Blood 1989; 73: 747-52.
29. Maas RA, Bruning PF, Breedijk AJ et al. Methods in laboratory investigation. Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates. Lab Invest 1995; 6: 760-764.
30. O'Driscoll L, Kennedy S, McDermott E et al. Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue. Eur J Cancer 1996; 32A: 128-33.
31. Schneider J, Rubio MP, Barbazán MJ et al. P-Glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994; 86: 850-5.
32. Veneroni S, Zaffaroni N, Daidone MG et al. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994; 30A: 1002-7.
33. Decker DA, Morris LW, Levine AJ et al. Immunohistochemical analysis of P-glycoprotein expression in breast cancer: Clinical correlations. Ann Clin Lab Science 1995; 25: 52-59.
34. Rouyer N, Lambolais C, Chenard MP et al. Stromelysin-3 (ST3) and P-glycoprotein (PGP) as predictive factors in inflammatory breast carcinoma (IBC). Proc Am Soc Clin Oncol 1995; 14: 42.
35. Verrelle P, Meissonnier F, Fonck Y et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83: 111-6.
36. Rao VV, Anthony DC, Piwnica-Worm D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994; 54: 1536-40.
37. Thiebaut F, Tsuruo T, Hamada H et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transporter protein P170: Evidence for localization in brain capillaries and cross reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-64.
38. Flynn SD, Murren JR, Kirby WM et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112: 981-6.
39. Kelly DJ, Pavelic ZP, Gapany M et al. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1993; 119: 411-4.